For applications in biodefense, it is desirable for small molecule inhibitors to target multiple category A-C agents, because it is difficult and expensive to develop even one small molecule inhibitor. Relatively few clinically useful drugs are active against multiple different pathogens. Of the few that are, a substantial fraction target DMA modifying enzymes. Examples include topoisomerase inhibitors used as antimicrobials against many bacteria, and nucleotide reverse transcriptase inhibitors used against HIV and HBV. In our previous MARCE-funded projects, we have initiated development of therapeutics for two DMA modifying enzymes that are found in multiple category A-C agents. One is a type 1B topoisomerase, the second a Holliday junction resolvase. Initial studies focused on examples of these enzymes found in poxviruses. We have established assays in vitro and used them to screen -225,000 small molecules for inhibitory activity at the Northeast RCE Screening Facility and at Merck Research Laboratories. We have also carried out background mechanistic studies to inform our efforts at inhibitor design. Results include 1) collaborating to solve the structure of the variola topoisomerase enzyme bound to DMA and 2) revising our understanding of favored substrates for the vaccinia resolvase. We have identified molecules with activity against each purified protein in vitro and against poxvirus replication in cell culture assays. We propose to use these as starting points to find inhibitors active against both poxviruses and Coccidioides, the fugus responsible for Valley Fever, which was recently added to the select agent list and encodes a resolvase resembling the poxvirus enzyme. Going forward, we will develop our lead inhibitors and carry out mechanistic studies to aid inhibitor development. This project is intended for Research Program I, since it concerns the use of small molecule inhibitors to modulate interactions of Emerging Viruses with Host Cell Pathways, but we also expect to have extensive interactions with programs IV and VI.

Public Health Relevance

The goal of this project is to generate therapeutics against Category A-C agents. We are studying two molecular targets present in multiple Category A-C agents, so single inhibitors active against each target have the potential to treat infection by multiple different microbes.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
United States
Zip Code
Freedman, John C; Theoret, James R; Wisniewski, Jessica A et al. (2015) Clostridium perfringens type A-E toxin plasmids. Res Microbiol 166:264-79
Li, Jihong; McClane, Bruce A (2014) Contributions of NanI sialidase to Caco-2 cell adherence by Clostridium perfringens type A and C strains causing human intestinal disease. Infect Immun 82:4620-30
Moy, Ryan H; Gold, Beth; Molleston, Jerome M et al. (2014) Antiviral autophagy restrictsRift Valley fever virus infection and is conserved from flies to mammals. Immunity 40:51-65
Cuevas, Christian D; Ross, Susan R (2014) Toll-like receptor 2-mediated innate immune responses against Junín virus in mice lead to antiviral adaptive immune responses during systemic infection and do not affect viral replication in the brain. J Virol 88:7703-14
Boyd, Mary Adetinuke; Tennant, Sharon M; Saague, Venant A et al. (2014) Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines. Clin Vaccine Immunol 21:712-21
Su, Yi-Hsuan; Tsegaye, Mikiyas; Varhue, Walter et al. (2014) Quantitative dielectrophoretic tracking for characterization and separation of persistent subpopulations of Cryptosporidium parvum. Analyst 139:66-73
Xu, Jie; Cherry, Sara (2014) Viruses and antiviral immunity in Drosophila. Dev Comp Immunol 42:67-84
Uzal, Francisco A; Freedman, John C; Shrestha, Archana et al. (2014) Towards an understanding of the role of Clostridium perfringens toxins in human and animal disease. Future Microbiol 9:361-77
Weir, Dawn L; Laing, Eric D; Smith, Ina L et al. (2014) Host cell virus entry mediated by Australian bat lyssavirus G envelope glycoprotein occurs through a clathrin-mediated endocytic pathway that requires actin and Rab5. Virol J 11:40
Weir, Dawn L; Annand, Edward J; Reid, Peter A et al. (2014) Recent observations on Australian bat lyssavirus tropism and viral entry. Viruses 6:909-26

Showing the most recent 10 out of 299 publications